Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 4/20 | 0.48 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.48 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | SHBG | P04278 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6694162 | 0.99 | SRD5A2 (0.49) | SRD5A2SRD5A1ARSHBG | |
| SCHEMBL8080858 | 0.89 | SRD5A2 (0.50) | SRD5A2SRD5A1AR | |
| SCHEMBL8080861 | 0.89 | SRD5A2 (0.50) | SRD5A2SRD5A1AR | |
| SCHEMBL9066010 | 0.81 | SRD5A1 (0.51) | SRD5A2SRD5A1AR | |
| SCHEMBL9066006 | 0.81 | SRD5A1 (0.51) | SRD5A2SRD5A1AR | |
| SCHEMBL6700170 | 0.79 | SRD5A2 (0.46) | SRD5A2SRD5A1ARSHBG | |
| SCHEMBL9066310 | 0.78 | SRD5A2 (0.47) | SRD5A2SRD5A1ARSHBG | |
| SCHEMBL7072009 | 0.77 | HSD17B7 (0.54) | SRD5A2SRD5A1 | |
| SCHEMBL6701113 | 0.76 | SRD5A2 (0.47) | SRD5A2SRD5A1ARSHBG | |
| SCHEMBL10894849 | 0.75 | SHBG (0.67) | SRD5A2ARSHBG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082556-A1 | Inhibitors of type 5 and type 3 17beta-hydroxysteroid dehydrogenase and methods for their use | ENDORECHERCHE, INC. | 2004-04-29 | — | — | US | disclosed |
| EP-1321146-A2 | Inhibitors of type 5 and 3 17beta-hydroxysteroid dehydrogenase and methods for their use | Endorecherche Inc. (CA) | 2003-06-25 | — | — | EP | disclosed |
| US-6541463-B1 | 17-spirolactone derivatives of steroids | ENDORECHERCHE, INC. (CA) | 2003-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082556-A1 | Inhibitors of type 5 and type 3 17beta-hydroxysteroid dehydrogenase and methods for their use | HSD17B11, HSD17B3, HSD17B1 | SRD5A2 8/4885SRD5A1 5/4885AR 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.